Loading
A phase 1/2 trial of Selpercatinib in thyroid cancer and sarcomas, run by Eli Lilly and Company, active and no longer recruiting.
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors is a phase 1/2 interventional study registered as NCT03899792 by Eli Lilly and Company, with 36 participants enrolled, started 2019-06-13 and due to reach its primary completion in 2024-11-08. Interventions recorded: Selpercatinib. Conditions listed: Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
36 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2026-01-06), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Phase 2: Percentage of Participants With Overall Response Rate (ORR) in Studyprimary | Cohort 1 (Phase 2): MTC Group | 15 | 60% | - | - | link |
| Cohort 2 (Phase 2): PTC Group | 15 | 53.3% | ||||
| Cohort 3 (Phase 2): Other Cancer Group | 6 | 33.3% |
Shares Selpercatinib, Eli Lilly (incl. Loxo), Thyroid cancer, Small-molecule kinase inhibitors.
Shares Eli Lilly (incl. Loxo), Sarcomas (soft tissue, bone, GIST), Small-molecule kinase inhibitors.
Shares Selpercatinib, Thyroid cancer, Small-molecule kinase inhibitors.
Shares Selpercatinib, Eli Lilly (incl. Loxo), Small-molecule kinase inhibitors.
Shares Eli Lilly (incl. Loxo), Small-molecule kinase inhibitors.
Shares Selpercatinib, Eli Lilly (incl. Loxo), Thyroid cancer, Small-molecule kinase inhibitors.
Shares Eli Lilly (incl. Loxo), Small-molecule kinase inhibitors.
Shares Eli Lilly (incl. Loxo), Small-molecule kinase inhibitors.